EVE is a deep generative model combining evolutionary and human population data to estimate variant deleteriousness on a proteome-wide scale.
The U.S. Pharmacopeia has created new standards to support the emerging field of advanced cell and gene therapies.
Precipitation-based purification method could replace current Protein A–reliant methods, significantly reducing manufacturing costs of mAbs.
Sustainable bioprocessing boosts cyanobacterial pigment production for advanced biomedical, imaging, and commercial applications.
Multiple microbial communities populate cleanrooms, regardless of grade, and aren’t detected by standard monitoring methods.
The U.S. is AstraZeneca’s largest market by sales and is also home to 19 R&D, manufacturing, and commercial sites.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback